Bayer - investor.bayer.com
General Information:
Latest News:
27.08.13: Not intended for U.S. and UK Media 27 Aug 2013 | 09:30 am
Nexavar® (sorafenib) Granted Priority Review for Differentiated Thyroid Cancer in the U.S. Currently no approved therapies specifically for differentiated thyroid cancer refractory to radioactive iod...
20.08.13: Not intended for U.S. and UK Media 20 Aug 2013 | 10:05 am
Bayer's Stivarga® Approved for the Treatment of Patients with Gastrointestinal Stromal Tumors in Japan mehr ...
06.08.13: Not intended for U.S. and UK Media - Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension: 7 Aug 2013 | 12:55 am
U.S. FDA Advisory Committee Unanimously Recommends Approval of Bayer's Riociguat in Two Forms of Pulmonary Hypertension mehr ...
06.08.13: Not intended for U.S. and UK Media 6 Aug 2013 | 09:35 am
VEGF Trap-Eye (aflibercept solution for injection) Met Primary Endpoint in Two Phase 3 Trials for the Treatment of Diabetic Macular Edema mehr ...
31.07.13: Second quarter of 2013: 31 Jul 2013 | 08:30 am
Bayer: strong growth in Life Sciences HealthCare and CropScience post dynamic growth, MaterialScience weak / New pharmaceutical products well above expectations / Group sales rise 1.9 percent (Fx & p...
26.07.13: Not intended for U.S. and UK Media 26 Jul 2013 | 04:05 pm
Bayer Receives Recommendation for Approval of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Visual Impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion...
01.07.13: Bayer completes acquisition of Steigerwald 1 Jul 2013 | 01:30 pm
Bayer completes acquisition of Steigerwald Christian Sarto appointed Managing Director mehr ...
01.07.13: Not intended for U.S. and UK Media 1 Jul 2013 | 09:35 am
Sorafenib (Nexavar®) Submitted to the EMA and FDA for the Treatment of Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer Currently no approved therapies speci...
28.06.13: Not intended for U.S. and UK Media 28 Jun 2013 | 03:35 pm
U.S. FDA Issues Complete Response Letter for Bayer's Xarelto® to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome mehr ...
28.06.13: Not intended for U.S. and UK Media 28 Jun 2013 | 03:30 pm
Bayer's Regorafenib Recommended for Approval in the European Union for the Treatment of Metastatic Colorectal Cancer Regorafenib shown in a pivotal Phase III trial to extend overall survival in patie...
